Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases - a claims data analysis.

ABSTRACT:

Background

Interstitial lung diseases (ILDs) are associated with a high burden of disease. However, data on the prognostic impact of comorbidities and comorbidity-related pharmaceutical treatments in patients with various ILDs remain sparse.

Methods

Using longitudinal claims data from a German Statutory Health Insurance Fund, we assessed comorbidity in ILD subtypes and associated drug treatments. Baseline comorbidity was assessed via the Elixhauser Comorbidity Index that was amended by ILD-relevant conditions. Drug treatment was assessed on the substance level using the ATC-codes of drugs prescribed at the time of ILD diagnosis. Subsequently, the comorbid conditions (main analysis) and pharmaceutical substances (secondary analysis) with a meaningful association to survival w

SUBMITTER: Schwarzkopf L 

PROVIDER: S-EPMC5918773 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature